Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • How to stop a stroke in its tracks

  • Significant increase in major depression reported during recent recession

  • Discovery may open door for treating fragile X carriers

  • Fat tissue controls brain's response to food scarcity, helping regulate optimal amount of body fat for brain function

  • Risk perception: Social exchange can amplify subjective fears

  • Psychology of the appeal of being anti-GMO

  • New light shed on brain's source of power

  • We think better on our feet, literally

  • Inclusive classrooms don't necessarily increase friendships for children with disabilities

  • New insight into how brain makes memories

  •